Roche Considers Divesting $1.9 Billion Cancer Data Startup
Swiss pharmaceutical giant Roche is reportedly considering options for its cancer data specialist, Flatiron Health, which it acquired for $1.9 billion in 2018. This move aimed to accelerate the development of cancer medicines and support pricing strategies based on treatment efficacy.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
